Conolidine’s analgesic outcomes stem from its conversation with non-opioid pain pathways. Compared with opioids, which bind to µ-opioid receptors inside the central anxious program, conolidine modulates alternate molecular targets. A Science Innovations research found that conolidine interacts Using the atypical chemokine receptor ACKR3/CXCR7, which regulates opioid peptide availabili... https://geneu678pcp8.liberty-blog.com/profile